REZOLUTE, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
REZOLUTE, INC. (RZLT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.64 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-09-24
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-09-30 was $7.71, a 63.00% increase year-over-year.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-09-30 was $4.73, a 213.25% increase year-over-year.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-09-30 was $1.51.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-09-30 was $8.96.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2026 was $8.64, a 89.06% increase from fiscal 2025.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $4.57, a 248.85% increase from fiscal 2024.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.31, a 34.50% decline from fiscal 2023.
- REZOLUTE, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.64 10-K · filed 2026-09-24 | ||||||
| 2026-03-31 | $9.16 10-Q · filed 2026-05-12 | ||||||
| 2025-12-31 | $9.23 10-Q · filed 2026-02-12 | ||||||
| 2025-09-30 | $7.71 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | $4.57 10-K · filed 2026-09-24 | ||||||
| 2025-03-31 | $4.65 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | $4.97 10-Q · filed 2025-02-12 | ||||||
| 2024-09-30 | $4.73 10-Q · filed 2024-11-07 | ||||||
| 2024-06-30 | $1.31 10-K · filed 2025-09-17 | ||||||
| 2024-03-31 | $1.18 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | $1.44 10-Q · filed 2024-02-13 | ||||||
| 2023-09-30 | $1.51 10-Q · filed 2023-11-13 | ||||||
| 2023-06-30 | $2.00 10-K · filed 2024-09-19 | ||||||
| 2023-03-31 | $1.98 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | $2.12 10-Q · filed 2023-02-10 | ||||||
| 2022-03-31 | $5.37 10-Q · filed 2022-05-12 | ||||||
| 2021-12-31 | $7.69 10-Q · filed 2022-02-09 | ||||||
| 2021-09-30 | $8.96 10-Q · filed 2021-11-12 | ||||||
| 2021-03-31 | $19.50 10-Q · filed 2021-05-17 | ||||||
| 2020-12-31 | $19.50 10-Q · filed 2021-02-10 | ||||||
| 2019-12-31 | $0.29 10-Q · filed 2020-02-12 | ||||||
| 2019-09-30 | $0.29 10-Q · filed 2019-11-14 | ||||||
| 2019-06-30 | $0.52 10-K · filed 2019-09-10 | ||||||
| 2019-03-31 | $0.52 10-Q · filed 2019-05-10 | ||||||
| 2018-12-31 | $0.52 10-Q · filed 2019-02-14 | ||||||
| 2018-09-30 | $0.52 10-Q · filed 2018-12-14 | ||||||
| 2018-06-30 | $1.08 10-K · filed 2019-09-10 | ||||||
| 2018-03-31 | $1.08 10-Q · filed 2018-05-15 | ||||||
| 2017-12-31 | $1.08 10-Q · filed 2018-02-14 | ||||||
| 2017-09-30 | $1.15 10-Q · filed 2017-11-14 | ||||||
| 2017-06-30 | $1.19 10-K · filed 2018-10-15 | ||||||
| 2016-06-30 | $1.07 10-K · filed 2017-09-22 | ||||||
| 2014-06-30 | $3.14 10-K · filed 2014-09-30 | ||||||
| 2014-03-31 | $3.12 10-Q · filed 2014-05-14 | ||||||
| 2013-06-30 | $4.50 10-Q · filed 2014-05-14 | $0.75 10-Q · filed 2013-11-12 | $4.50 10-K · filed 2014-09-30 | $0.75 10-K · filed 2013-09-11 | |||
| 2013-03-31 | $0.75 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |